Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

Cancers (Basel) · 2018 · PMC6210332 · PMID 30336605

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Compared to the baseline (d1, cycle 1), we revealed a highly significant increase of Ab levels from cycle to cycle (1.06 ± 0.06, 1.34 ± 0.09, 1.74 ± 0.15, and 1.99 ± 0.15 μg/mL for cycle 1, 2, 3, 4 and 5, respectively) ( Figure 3 B).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.